文献速递中医内科中药与中成药合理使用

四神丸通过NEMO/NLK信号通路改善三硝基苯磺酸诱导的慢性结肠炎

Sishen Wan® Ameliorated Trinitrobenzene-Sulfonic-Acid-Induced Chronic Colitis via NEMO/NLK Signaling Pathway.
PubMed 文献 · Front Pharmacol · 2019-03-06

本研究探讨四神丸(SSW)治疗慢性结肠炎是否通过NF-κB信号通路。采用三硝基苯磺酸诱导的大鼠慢性结肠炎模型,SSW降低结肠重量指数、宏观和微观评分,减少钙卫蛋白和氧化损伤,下调IFN-γ、IL-1β、IL-17,上调IL-4,抑制NF-κB p65和NEMO样激酶(NLK)表达,并抑制泛素化NEMO及下游蛋白磷酸化。结果表明SSW通过抑制NEMO/NLK信号通路抑制NF-κB活化发挥治疗作用。

要点

  • 四神丸可改善三硝基苯磺酸诱导的大鼠慢性结肠炎。
  • 四神丸下调促炎因子并上调IL-4,减轻氧化损伤。
  • 其机制与抑制NEMO/NLK通路进而抑制NF-κB活化有关。

核心结论

  • 四神丸治疗慢性结肠炎的作用由抑制NEMO/NLK信号通路以抑制NF-κB活化所介导。

研究设计与样本

  • 采用三硝基苯磺酸诱导的大鼠慢性结肠炎模型,观察四神丸的治疗效果及对NF-κB信号通路的影响。

主要发现

  • 四神丸降低结肠重量指数、宏观和微观评分,并改善病理观察。
  • 四神丸降低结肠黏膜钙卫蛋白水平并消除氧化病变。
  • 四神丸下调干扰素-γ、白介素-1β和白介素-17表达,上调白介素-4表达。
  • 四神丸抑制NF-κB p65和NF-κB必需调节因子(NEMO)样激酶(NLK)表达。
  • 四神丸抑制泛素化NEMO、泛素激活酶和E2i活化,以及下游蛋白(cylindromatosis蛋白、转化生长因子-β激活激酶和P38)磷酸化。

临床怎么用

  • 四神丸作为经典中成药,可用于慢性结肠炎治疗,其机制涉及抑制NEMO/NLK通路。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The nuclear factor (NF)-κB signaling pathway plays an important role in the initialization and development phase of inflammatory injuries, including inflammatory bowel disease (IBD). Sishen Wan (SSW) is a classic Chinese patent medicine listed in the Chinese Pharmacopoeia, which is usually used to treat chronic colitis; however, it is unclear whether SSW can treat IBD via the NF-κB signaling pathway. In the present study, the therapeutic effect of SSW was demonstrated by the decreased index of colonic weight, macroscopic and microscopic score, and pathological observation in chronic colitis induced by trinitrobenzene sulfonic acid. In colonic mucosa of rats with chronic colitis, SSW reduced the levels of calprotectin and eliminated oxidative lesions; downregulated expression of interferon-γ, interleukin (IL)-1β and IL-17; increased expression of IL-4; and suppressed expression of NF-κB p65, and NF-κB essential modulator (NEMO)-like kinase (NLK). Furthermore, SSW inhibited ubiquitinated NEMO, ubiquitin-activated enzyme, and E2i activation, and phosphorylation of downstream proteins (cylindromatosis protein, transforming growth factor-β-activated kinase and P38). These results show that the therapeutic effects of SSW in chronic colitis were mediated by inhibiting the NEMO/NLK signaling pathway to suppress NF-κB activation.

来源:Front Pharmacol,查看原文。版权归原作者所有。

引用

  1. Wang HY, Zhao HM, Wang Y, et al. Sishen Wan® Ameliorated Trinitrobenzene-Sulfonic-Acid-Induced Chronic Colitis via NEMO/NLK Signaling Pathway. Front Pharmacol. 2019. PMID: 30894816. doi:10.3389/fphar.2019.00170

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。